Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases
Open Access
- 24 September 2020
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 152 (1) , 15-25
Abstract
Background: Although melanoma brain metastases (MBM) tend to respond to systemic therapy concordantly with extracranial metastases, little is known about differences in immune cell and vascular content between the brain and other metastatic sites. Here we studied infiltrating immune cell subsets and microvessel density (MVD) in paired intracerebral and extracerebral melanoma metastases. Methods: Paired intracerebral and extracerebral tumor tissue was obtained from 37 patients with metastatic melanoma who underwent craniotomy between 1997 and 2014. A tissue microarray was constructed to quantify subsets of tumor-infiltrating T-cell, B-cell, and macrophage content, PD-L1 expression, and MVD using quantitative immunofluorescence. Results: MBM had lower CD3+ (p = 0.01) and CD4+ (p = 0.003) T-cell content, lower MVD (p = 0.006), and a trend for lower CD8+ (p = 0.17) T-cell content compared to matched extracerebral metastases. There were no significant differences in CD20+ B-cell or CD68+ macrophage content, or tumor or stroma PD-L1 expression. Low MVD (p = 0.008) and high CD68+ macrophage density (p = 0.04) in intracerebral metastases were associated with improved 1-year survival from time of first MBM diagnosis. Conclusions: Although responses to immune-modulating drugs in the body and the brain tend to be concordant, differences were found in MVD and T-cell content between these sites. Studies of these markers should be incorporated into prospective therapeutic clinical trials to determine their prognostic and predictive value.Keywords
Funding Information
- National Cancer Institute (R01CA204002, K12CA215110)
- American Cancer Society (130157-RSG-16-216-01-TBG)
- Lung Cancer Research Foundation (Award#308721)
- Melanoma Research Alliance (Award#308721)
- National Institutes of Health (R01 CA216846, P50 CA121974, R01 CA227473, K12CA215110)
This publication has 32 references indexed in Scilit:
- GBM Volumetry using the 3D Slicer Medical Image Computing PlatformScientific Reports, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Prognostic factors for survival in melanoma patients with brain metastasesCancer, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Trafficking of immune cells in the central nervous systemJournal of Clinical Investigation, 2010
- C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of MelanomasClinical Cancer Research, 2009
- Vascularization of cutaneous melanoma involves vessel co‐option and has clinical significanceThe Journal of Pathology, 2002
- The current causes of death in patients with malignant melanoma1978